Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15065088rdf:typepubmed:Citationlld:pubmed
pubmed-article:15065088lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0034802lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0597360lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0205267lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C1515985lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0308269lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C1706701lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:15065088lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:15065088pubmed:issue4lld:pubmed
pubmed-article:15065088pubmed:dateCreated2004-4-5lld:pubmed
pubmed-article:15065088pubmed:abstractTextIntermittent androgen ablation is a palliative treatment option for advanced prostate cancer which is associated with less side effects, improved quality of life of patients, and reduced costs. Regulation of growth and survival of prostate cancer cells during intermittent androgen withdrawal has not been studied in appropriate models yet.lld:pubmed
pubmed-article:15065088pubmed:languageenglld:pubmed
pubmed-article:15065088pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15065088pubmed:citationSubsetIMlld:pubmed
pubmed-article:15065088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15065088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15065088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15065088pubmed:statusMEDLINElld:pubmed
pubmed-article:15065088pubmed:monthJunlld:pubmed
pubmed-article:15065088pubmed:issn0270-4137lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:BartschGeorgGlld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:RamonerReinho...lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:Artner-Dworza...lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:Godoy-Tundido...lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:HobischAlfred...lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:CuligZoranZlld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:FiechtlMatthi...lld:pubmed
pubmed-article:15065088pubmed:authorpubmed-author:Sandahl-Soren...lld:pubmed
pubmed-article:15065088pubmed:copyrightInfoCopyright 2004 Wileey-Liss, Inc.lld:pubmed
pubmed-article:15065088pubmed:issnTypePrintlld:pubmed
pubmed-article:15065088pubmed:day1lld:pubmed
pubmed-article:15065088pubmed:volume59lld:pubmed
pubmed-article:15065088pubmed:ownerNLMlld:pubmed
pubmed-article:15065088pubmed:authorsCompleteYlld:pubmed
pubmed-article:15065088pubmed:pagination401-8lld:pubmed
pubmed-article:15065088pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:meshHeadingpubmed-meshheading:15065088...lld:pubmed
pubmed-article:15065088pubmed:year2004lld:pubmed
pubmed-article:15065088pubmed:articleTitleProstate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.lld:pubmed
pubmed-article:15065088pubmed:affiliationDepartment of Urology, University of Innsbruck, Innsbruck, Austria.lld:pubmed
pubmed-article:15065088pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15065088lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15065088lld:pubmed